drugset / Trial / NCT02443337
A Study of LY3023414 and Necitumumab in Squamous Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to evaluate the safety and activity of the study drug known as LY3023414 in combination with necitumumab in participants with metastatic squamous non-small cell lung cancer (NSCLC).
Timeline
- Start
- 2015-07
- Primary completion
- 2017-09
- Completion
- 2017-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Necitumumab | Monoclonal antibody | 800 mg | Intravenous |
| Subject | Samotolisib | Small molecule | 200 mg | Oral |